The Oncolytic Adenovirus Ad-E1A in the Gene Therapy of Mouse Ascitic Hepatoma in Vivo and Its Effect on Immune Function

CAO Jing-yuan,YANG Bi-wen,QIN Yue-xiang,JIAO Yu-juan,WANG Xiao-hua,WANG Jin-zhi,SHENG Wei-hua,YANG Ji-cheng,MIAO Jing-cheng

2010-01-01

Abstract:Objective To research the gene therapy of mouse ascitic hepatoma and its effect on immune function by oncolytic adenovirus Ad-E1A. Methods The E1A recombined adenovirus was proliferated in QBI-293A cells. RT-PCR was used to confirm the transcription of E1A gene in mouse hepatoma H22 cells. The tumor subcutaneous model was established with mouse ascitic hepatoma. The antitumor inhibitive ratio,thymus index,spleen index,and the number of white blood cell,lymphocyte,neutrophil and monocyte in every group were detected. Results The high titer E1A recombined adenovirus was obtained( The titer is 7 × 109pfu/ml) . In tumor subcutaneous model,compared with PBS group,the inhibitive ratio of Ad-E1A and 5-Fu was 66. 7% and 68. 8% respectively( P 0. 05) . Compared with invariable Ad-E1A group and PBS group,the thymus index and spleen index of 5-Fu were decreased obviously( P 0. 01 P 0. 05) . The number of white blood cells were equivalence between Ad-E1A group and nontumor group,while the group of 5-Fu were drop rapidly( P 0. 01) . The number of lymphocyte,neutrophil and monocyte were decreased obviously in 5-Fu group. Conclusion The oncolytic adenovirus AdE1A inhibite H22 ascitic hepatoma obviously,and almost has no side effect on immune function.